For an accessible version of this Press Release, please visit www.tevapharm.com Teva reports revenues of $4.5 billion in the third quarter of 2025, an increase of 3% year-over-year (YoY) in U.S. dollars or 1% in local currency (LC). Excluding Japan BV in Q3 2024, revenues increased 5% in U.S. dollars or 3% in LC. United States segment increased by 12%; Europe segment decreased by 10% in LC; and International Markets segment... Read More

This football season, Teva is increasing education around tardive dyskinesia (TD) by launching ‘The Other TD’ campaign TD is a chronic movement disorder impacting one in four people who take certain prescription mental health medications. While TD can impact your daily life, it can be treated without interrupting your mental health treatment 1 - 4 Younger individuals, men, and racial and ethnic minority groups have lower... Read More

TEL AVIV, Israel, Oct. 31, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that Richard Francis, Teva's President and CEO, will present at two upcoming investor conferences in November as follows: UBS Global Healthcare Conference Monday, November 10, 2025, at 8:45 A.M. Eastern Time (ET) Jefferies London Healthcare Conference Tuesday, November 18, 2025, at 11:00 A.M.... Read More

Teva and Prestige announce a license and supply agreement for the commercialization of Prestige’s Tuznue ® , a biosimilar to Herceptin ® (trastuzumab) Tuznue ® received European Commission (EC) marketing authorization in September 2024 Partnership brings together both companies’ expertise in biosimilars TEL AVIV, Israel, Oct. 20, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals International GmbH, a subsidiary of Teva... Read More

FDA approves UZEDY ® (risperidone) extended-release injectable suspension for subcutaneous use as monotherapy or as adjunctive therapy to lithium or valproate for the maintenance treatment of bipolar I disorder in adults. 1 UZEDY (risperidone) extended-release injectable suspension for subcutaneous use is indicated for use every one or two months for the treatment of schizophrenia in adults. 1 This approval marks a... Read More

TEL AVIV, Israel, Sept. 25, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that its Q3 2025 Aide Memoire is available on the “Investors” page on its website. Q3 2025 Aide Memoire Teva has prepared this document to assist in the financial modeling of its quarterly results. The document is based on Teva’s prior results, management’s previous commentary about Teva’s business... Read More

TEL AVIV, Israel, Sept. 25, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it will issue a press release on its third quarter 2025 financial results on Wednesday, November 5, 2025, at 7:00 a.m. ET. Following the release, Teva will conduct a conference call and live webcast on the same day, at 8:00 a.m. ET. In order to participate, please register in advance here to... Read More

Of the 209 patients with tardive dyskinesia (TD) that were surveyed, >94% reported movement improvement once treated with AUSTEDO XR ® (deutetrabenazine) extended-release tablets Patients reported high satisfaction (>89%) with AUSTEDO XR, with 96% expressing interest in continuing treatment Almost all (>96%) patients relayed that AUSTEDO XR was easy to take PARSIPPANY, N.J. and TEL AVIV, Israel, Sept. 20, 2025 (GLOBE... Read More

Through Week 56 in the SOLARIS trial, there were no suspected or confirmed post-injection delirium/sedation syndrome (PDSS) events observed with olanzapine LAI (TEV-'749) and its long-term systemic safety profile was consistent with other olanzapine formulations 1 Additional new data comparing initiation of UZEDY ® (risperidone) versus Invega Sustenna ® (paliperidone palmitate) in hospitalized patients found that UZEDY was... Read More

TEL AVIV, Israel, Sept. 16, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced plans to present data from the completed phase 3 SOLARIS trial at the 2025 Psych Congress Annual Meeting, taking place from September 17 – 21, 2025, in San Diego, California. Teva will also host a conference call for analysts and investors on Monday, September 22, 2025, at 11:00 a.m. ET to discuss... Read More

Teva received Fast Track designation from the U.S. Food and Drug Administration for emrusolmin (TEV-56286), an investigational treatment for Multiple System Atrophy (MSA) in Phase 2 development. New therapeutic options for people living with MSA, a rare and devastating neurodegenerative disorder, are urgently needed as there are no treatments available that impact disease progression. Emrusolmin is a small molecule that... Read More

TEL AVIV, Israel, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that Richard Francis, Teva's President and CEO, will present at two upcoming investor conferences in September as follows: Morgan Stanley 23rd Annual Global Healthcare Conference Tuesday, September 9, 2025, at 8:30 A.M. ET BofA Global Healthcare Conference 2025 (London) Wednesday, September 24, 2025,... Read More

Generic Saxenda ® is the first-ever generic GLP-1 indicated for weight loss, addressing increased demand for this category of therapies in the U.S. market. This approval and launch add to Teva’s continued commitment to its complex generic medicine portfolio as part of its Pivot to Growth Strategy. Liraglutide injection is indicated for adults with obesity or overweight (excess weight) who also have weight related medical... Read More

FDA approves single-dose AJOVY ® (fremanezumab-vfrm) injection for the preventive treatment of episodic migraine in children and adolescents aged 6-17 who weigh 45 kilograms or more, offering a long-awaited monthly treatment option with in-office or at-home administration 1 AJOVY expands access across age groups as the first and only calcitonin gene-related peptide (CGRP) antagonist approved for pediatric episodic migraine... Read More

On track for 30% operating profit margin by 2027 in line with our Pivot to Growth Strategy. Q2 2025 shows 10 th consecutive quarter of year-over-year (YoY) revenue growth; Revenues of $4.2 billion, +1% in local currencyterms (“LC“)excluding Japan BV revenues; United States segment +2%; Europe segment +3% in LC; International Markets segment -4% inLCand excluding Japan BV revenues. Innovative portfolio continues to fuel... Read More

TEL AVIV, Israel, June 26, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that its Q2 2025 Aide Memoire is available on the “Investors” page on its website. Q 2 2025 Aide Memoire Teva has prepared this document to assist in the financial modeling of its quarterly results. The document is based on Teva’s prior results, management’s previous commentary about Teva’s business... Read More

TEL AVIV, Israel, June 25, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it will issue a press release on its second quarter 2025 financial results on Wednesday, July 30, 2025, at 7:00 a.m. ET. Following the release, Teva will conduct a conference call and live webcast on the same day, at 8:00 a.m. ET. In order to participate, please register in advance here to obtain... Read More

Final analysis of PEARL real world migraine prevention study presented at 11th Congress of the European Academy of Neurology (EAN 2025) Congress in Helsinki 1 , 2 Fremanezumab demonstrated sustained effectiveness and a favourable safety and tolerability profile over the two-year study period 1 , 2 Injection adherence remained high throughout the study (~90%), while over 75% of patients completed the study duration 1 TEL... Read More

Teva-engineered TEV-56278 is an anti-PD1-IL2 ATTENUKINE™ therapy in Phase 1 for the treatment of various forms of cancer, including melanoma Fosun Pharma-Teva collaboration agreement established with goal of accelerating clinical data generation for TEV-56278 Partnership leverages strategic relationships to enable research and development of innovative treatments to advance Teva's Pivot to Growth strategy TEL AVIV, Israel... Read More

TEL AVIV, Israel, June 03, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) (“ Teva ”) announced today the pricing and early acceptance results of its previously announced tender offers (the “ Offers ”) to purchase for cash the outstanding notes issued by finance subsidiaries of Teva and guaranteed by Teva of the series described in the table below (the “ Notes ”) upon the terms of, and... Read More

TEL AVIV, Israel, June 03, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) (“ Teva ”) announced today the early tender results in connection with its previously announced tender offers (the “ Offers ”) as specified below for the following series of notes issued by finance subsidiaries of Teva and guaranteed by Teva: USD 3.150% Senior Notes due 2026, CUSIP 88167AAE1 / ISIN US88167AAE10... Read More

More than half of residents with tardive dyskinesia (TD) residing in long-term care (LTC) settings do not receive standard of care treatment, and one-quarter are left untreated LTC residents are often given a broader diagnosis of extrapyramidal syndrome, which can lead to incorrect treatment options for TD Teva is committed to continuing to advance research to better understand and help address unmet needs among patients... Read More

Real-world claims studies evaluating UZEDY ® (risperidone) also show improved adherence and persistence rates, fewer inpatient, outpatient and emergency department (ED) visits versus second-generation daily oral options Latest Phase 3 SOLARIS data show no suspected or confirmed PDSS events with TEV-'749 after more than 3,400 subcutaneous injections in study participants to date As a leader in neuroscience, Teva is committed... Read More

Teva outlines acceleration path into a leading biopharma company Innovative medicines franchise on track to exceed $5 billion by 2030, led by AUSTEDO ® (deutetrabenazine), AJOVY ® (fremanezumab), UZEDY ® (risperidone) and late-stage pipeline with blockbuster potential Reaffirming 2027 financial targets, including 30% operating profit margin, driven by innovative growth and transformation programs TEL AVIV, Israel and... Read More

Fast Track designation granted for investigational TEV-53408, an anti-IL-15 antibody Designation underscores the potential of TEV-53408, currently undergoing a Phase 2a study for the treatment of celiac disease Candidate demonstrates Teva’s commitment to bringing important new treatment options to underserved patient populations TEL AVIV, Israel, May 27, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries, Ltd. (NYSE and... Read More

TEL AVIV, Israel, May 27, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that members of its executive management team will present at two upcoming investor conferences in June as follows: Jefferies Global Healthcare Conference Chris Fox, EVP U.S. Commercial and Dr. Eric Hughes, EVP Global R&D and Chief Medical Officer Wednesday, June 4, 2025, at 9:20 am ET Goldman Sachs 46... Read More

BD9 is a multibody that targets IL-13 and TSLP, and has potential to treat TH-2-driven inflammatory diseases BD9 designed using Biolojic’s Multibody Platform, which generates Antibodies capable of addressing multiple disease targets Collaboration builds on Teva’s Pivot to Growth strategy to step up innovation in Teva’s innovative pipeline REHOVOT, Israel and WASHINGTON and TEL AVIV, Israel, May 27, 2025 (GLOBE NEWSWIRE) --... Read More

TEL AVIV, Israel, May 22, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) (“ Teva ”) announced today that it is increasing the maximum tender amount of its tender offer previously announced on May 19, 2025 from $2.0 billion (equivalent) aggregate cash purchase price (exclusive of accrued and unpaid interest) to approximately $2.25 billion (equivalent) aggregate cash purchase price... Read More

TEL AVIV, Israel, May 20, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) (“ Teva ”) announced today that it successfully upsized its offering and priced approximately $2,300,000,000 (equivalent) of its senior notes (the “ Notes ”). The principal amount of the offering was increased from the previously announced offering size of $2,000,000,000 (equivalent). Teva expects to use the net... Read More

TEL AVIV, Israel, May 20, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals (NYSE and TASE: TEVA) today announced that Fitch Ratings Agency (“Fitch”) has raised the Company's corporate credit rating to BB+, with a stable outlook; from BB. Fitch's report cites Teva's progress in reducing debt and improving flexibility, expects continuous revenue growth from AUSTEDO and AJOVY, as well as Teva's biosimilar pipeline. In addition,... Read More

TEL AVIV, Israel, May 19, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) (“ Teva ”) announced today its intention to issue $2,000,000,000 (equivalent) of senior notes through its special purpose finance subsidiaries. Teva Pharmaceutical Finance Netherlands II B.V. (“ Teva Finance II ”) intends to offer EUR-denominated Senior Notes (the “ Euro Notes ”) and Teva Pharmaceutical Finance... Read More

TEL AVIV, Israel, May 19, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) (“ Teva ”) announced today that it has commenced tender offers (the “ Offers ”) to purchase for cash for a combined aggregate purchase price (exclusive of accrued and unpaid interest) of up to $2,000,000,000 (equivalent) (the “ Total Maximum Amount ”) of the following series of notes issued by finance subsidiaries of... Read More

TEL AVIV, Israel, May 15, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals (NYSE and TASE: TEVA) today announced that Moody's Investor Services (“Moody's”) has raised the company's corporate credit rating to Ba1, outlook stable; from Ba2, outlook positive. Moody's report cites the Company's strengths which include significant global scale, ongoing growth in the company’s branded franchises, stabilization of the company’s... Read More

The Company achieved a 29% reduction in absolute scope 1 and 2 greenhouse gas emissions from 2019 levels, surpassing its target of 25% by 2025, ahead of schedule Teva launched two new programs to help people around the world access the medicines they need, for a total of nine programs, surpassing its target of eight programs by 2025 More than 99% of Teva employees were trained on compliance and ethics, and more than 40% of... Read More

TEL AVIV, Israel, May 07, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it will host Innovation & Strategy Day on Thursday, May 29, 2025 to discuss the acceleration phase of its strategy and portfolio priorities. The event will take place in New York, N.Y. Presentations will begin at 8:30 a.m. Eastern Time and are expected to conclude at 12:30 p.m. Eastern Time.... Read More

On track for 30% operating profit margin by 2027 in line with our Pivot to Growth Strategy; Q1 2025 shows ninth consecutive quarter of revenue growth, excluding revenues recorded for Sanofi collaboration. Q1 2025 revenues of $3.9 billion, an increase of 5%; net of $100 million foreign exchange impact, reported revenues growth of 2%. AUSTEDO ® – shows continued strong growth, with worldwide revenues of $411 million in Q1... Read More

EPYSQLI ® (eculizumab-aagh) is now available to patients living with difficult-to-treat rare diseases like paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome and generalized myasthenia gravis in adults who are anti-acetylcholine receptor antibody positive EPYSQLI will be available at a 30% discount of the Wholesale Acquisition Cost (WAC) of the reference product, Soliris ® (eculizumab), making it one of... Read More

If approved for an expanded pediatric indication, AJOVY would be the first calcitonin gene-related peptide (CGRP) antagonist for migraine prevention in adults and episodic migraine prevention in pediatric patients, addressing the high unmet need for effective treatments AJOVY is currently the only anti-CGRP treatment for migraine prevention in adults in the U.S. that is available in both quarterly and monthly dosing options... Read More

More than 92% of schizophrenia patients taking TEV- ' 749 in the SOLARIS survey were satisfied or very satisfied with the initiation regimen, dosing schedule and trial medication 1 New data from UZEDY ® (risperidone) evaluated predictors of response in schizophrenia with efficacy observed across patient demographic and clinical characteristics in the Phase 3 RISE trial Teva continues its commitment to generating clinical... Read More

TEL AVIV, Israel, March 27, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it will issue a press release on its first quarter 2025 financial results on Wednesday, May 7, 2025, at 7:00 a.m. ET. Following the release, Teva will conduct a conference call and live webcast on the same day, at 8:00 a.m. ET. In order to participate, please register in advance here to obtain a... Read More

TEL AVIV, Israel, March 27, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that its Q1 2025 Aide Memoire is available on the “Investors” page on its website. Q1 2025 Aide Memoire Teva has prepared this document to assist in the financial modeling of its quarterly results. The document is based on Teva’s prior results, management’s previous commentary about Teva’s business... Read More

TEL AVIV, Israel, March 03, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that Richard Francis, Teva's President and CEO, will present at two upcoming investor conferences in March as follows: Barclays 27 th Annual Global Healthcare Conference Tuesday, March 11, 2025, at 8:00 am ET Leerink Partners Global Healthcare Conference Wednesday, March 12, 2025, at 8:40 am ET To... Read More

SANTA BARBARA, Calif. and PARSIPPANY, N.J. , Feb. 27, 2025 (GLOBE NEWSWIRE) -- Direct Relief, Teva Pharmaceuticals , and the National Association of Free and Charitable Clinics (NAFC) today announced the funding of Community Routes: Access to Mental Health Care grants, awarding $75,000 to each of 11 free and charitable clinics across Alabama, Mississippi, and Texas. Now in its third year, the initiative continues to address... Read More

UZEDY is currently approved in the US as a subcutaneous long-acting injectable (LAI) for use every one or two months for the treatment of schizophrenia in adults 1 LAI treatment options may help address unmet needs of people living with bipolar I disorder (BP-I) BP-I filing acceptance for UZEDY represents Teva’s commitment to pursuing new advances in neuroscience PARSIPPANY, N.J. and TEL AVIV, Israel and PARIS, Feb. 25, 2025... Read More

New detailed data from the RELIEVE UCCD study support overall efficacy and safety of duvakitug in all pre-specified subgroups across the different doses New endpoints presented include findings on clinical and endoscopic outcomes and histological- endoscopic mucosal improvement Findings to form the basis for a Phase 3 program, anticipated to start in H2 2025 PARSIPPANY, N.J. and PARIS, Feb. 22, 2025 (GLOBE NEWSWIRE) -- Teva... Read More

In October 2024, t he U. S. Food and Drug Administration (FDA) approved SELARSDI ™ for all indications matching the reference product Stelara ® ( ustekinumab ) and has granted a provisional determination of interchangeability for SELARSDI SELARSDI is the second biosimilar to launch in the U.S. under the Teva and Alvotech strategic partnership , which includes nine products SELARSDI is approved for the treatment of moderate... Read More

TEL AVIV, Israel, Feb. 18, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it will conduct a conference call and live webcast at 8 am E.T. on Monday, February 24, 2025. During the conference call, Eric Hughes, MD, PhD, Executive Vice President of Global R&D and Chief Medical Officer, and external IBD key opinion leaders (KOLs) will discuss new data presented for... Read More

REYKJAVIK, Iceland and PARSIPPANY, N.J., Feb. 18, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, and Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced that the U.S. Food and Drug Administration (FDA) has accepted for review a Biologics... Read More

2024 Revenues of $16.5 billion reflect an increase of 6%, in local currency terms, compared to 2023; AUSTEDO ® - exceeding $1.6 billion in revenues, surpassing 2024 outlook; AJOVY ® - global annual revenues of $507 million, an increase of 18% in local currency terms compared to 2023; UZEDY ® revenues of $117 million in 2024 surpassing $100M outlook; Generics business continues to grow across all segments, with increases of... Read More

REYKJAVIK, Iceland and PARSIPPANY, N.J., Jan. 27, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, and Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced that the U.S. Food and Drug Administration (FDA) has accepted for review Biologics... Read More

Klinge Biopharma GmbH (Klinge) holds the exclusive global commercialization rights for FYB203, Formycon's biosimilar candidate to Eylea ® 1 Agreement builds on the proven and successful collaboration of commercialization of FYB201, Formycon's biosimilar to Lucentis ® 2 (ranibizumab) in Europe The partnership broadens Teva's biosimilars portfolio, in line with its Pivot to Growth strategy TEL AVIV, Israel, Jan. 13, 2025... Read More

Marks a step forward in broadening treatment options for patients with paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS) and generalized myasthenia gravis (gMG) in the U.S. Partnership supports Teva's Pivot to Growth strategy and adds to its broad biosimilar portfolio INCHEON, Korea and TEL AVIV, Israel, Jan. 10, 2025 (GLOBE NEWSWIRE) -- Samsung Bioepis Co., Ltd. and Teva Pharmaceutical... Read More

TEL AVIV, Israel, Dec. 23, 2024 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that Richard Francis, Teva's President and CEO, will present at the 43 rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025. The presentation will begin at 8:15 A.M. Pacific Time (11:15 A.M. Eastern Time). To access a live webcast of the presentation, visit Teva’s Investor Relations... Read More

TEL AVIV, Israel, Dec. 20, 2024 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it will issue a press release on its fourth quarter and full year 2024 financial results, as well as on its financial guidance for 2025, on Wednesday, January 29, 2025, at 7:00 a.m. ET. Following the release, Teva will conduct a conference call and live webcast on the same day, at 8:00 a.m. ET.... Read More

Primary endpoints met in ulcerative colitis (UC) and Crohn’s disease (CD), the most common forms of inflammatory bowel disease (IBD) Primary endpoint results in UC and CD for high dose represent the highest achieved with any TL1A monoclonal antibody Sanofi and Teva plan to initiate Phase 3 development in IBD, pending regulatory discussions PARSIPPANY, N.J. and PARIS, Dec. 17, 2024 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals , a... Read More

Teva to provide two generic inhaler products to Direct Relief for its network of free and charitable clinics The program, launching this month, will run for a minimum of three years PARSIPPANY, N.J., Dec. 11, 2024 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, Inc. , a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), announced today the launch of a new patient access program, in partnership with Direct... Read More

Teva entered into an agreement with JKI Co., Ltd. (“JKI”) established by the fund managed and operated by private equity firm J-Will Partners Co., Ltd. ("J-Will”), through which JKI will acquire Teva-Takeda The agreement is aligned with Teva's Pivot to Growth strategy to focus its business The expected divestment of Teva-Takeda, Teva's business venture in Japan, which includes generics products and legacy products, will... Read More

AJOVY ® (fremanezumab) significantly reduced monthly migraine days (MMD) and monthly headache days (MHD) versus placebo over a 12-week period in pediatric patients aged 6-17 years 1 Efficacy consistent with fremanezumab pivotal Phase 3 and Real-World Evidence studies in adults with no new emergent safety signals observed Full data presented as a late breaker at European Headache Congress (EHC) 4-7 December in Rotterdam,... Read More

TEL AVIV, Israel, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that Richard Francis, Teva's President and CEO, and Eric Hughes, Teva’s Executive Vice President of Global R&D and Chief Medical Officer, will present at the 7 th Annual Evercore ISI HealthCONx Conference on Thursday, December 5, 2024. The presentation will begin at 8:20 A.M. Eastern Time. To access a... Read More

TEL AVIV, Israel, Nov. 08, 2024 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that Richard Francis, Teva's President and CEO, will present at the Jefferies London Healthcare Conference on Tuesday, November 19, 2024. The presentation will begin at 8:30 A.M. Greenwich Mean Time (3.30 A.M. Eastern Time). To access a live webcast of the presentation, visit Teva’s Investor Relations... Read More

For an accessible version of this Press Release, please visit www.tevapharm.com Q3 2024 revenues of $4.3 billion reflect an increase of 13% in U.S. dollars, or 15% in local currency terms, compared to Q3 2023. AUSTEDO ® – shows continued growth, U.S. revenues of $435 million in Q3 2024, an increase of 28% compared to Q3 2023; reaffirming 2024 revenue outlook of ~$1.6 billion. AJOVY ® – global revenues of $137 million in Q3... Read More

IMPACT-TD Registry, the largest study evaluating holistic effects of tardive dyskinesia (TD), highlights that there is a high burden of TD on quality of life regardless of a person’s underlying mental health condition Registry revealed fewer patients with psychotic disorders (36%) received TD diagnoses compared to those with mood disorders (50%) Teva continues to further innovations in mental health and progress real-world... Read More

Teva’s presentation of findings from six schizophrenia studies at Psych Congress 2024 highlights its commitment to finding new innovations in neuroscience Data show TEV-'749 drug delivery technology resulted in no occurrence of Post-Injection Delirium/Sedation Syndrome (PDSS) events to date Real-world analyses of UZEDY (risperidone) subcutaneous long-acting injectable reveal high adherence rates and utilization in adults... Read More

Teva Pharmaceuticals disagrees with the European Commission decision, which is based on legal theories that the company believes are extreme, untested, and factually unsupported The company intends to appeal the outcome and is fully prepared to mount its defense Teva has supported the MS community since 1996 and will not be distracted from providing access to this important standard-of-care treatment Teva works to the... Read More

Approval of SELARSDI 130 mg/26 mL in a single-dose vial for intravenous infusion expands label to include treatment of adults with Crohn’s disease and ulcerative colitis The FDA previously approved SELARSDI 45 mg/0.5 mL and 90 mg/mL in a single-dose prefilled syringe for subcutaneous injection in April 2024 SELARSDI’s U.S. launch for all indications is expected in Q1 2025 REYKJAVIK, Iceland & PARSIPPANY, N.J., Oct. 22, 2024... Read More

Prolia ® (denosumab) is indicated to treat certain conditions that lead to high risk for fracture, including osteoporosis in postmenopausal women TVB-009P, Teva’s proposed biosimilar to Prolia, showed Phase 3 clinical results in osteoporosis and is part of Teva’s robust biosimilar portfolio – 7 approved biosimilars and 16 in the pipeline – across critical therapeutic areas such as oncology, immunology and respiratory... Read More

The expansion of the strategic partnership reinforces the solid foundation of the collaborative efforts that commenced in April 2024 The collaboration supports Teva's Pivot to Growth strategy and adds to the company’s biosimilar portfolio Both companies reaffirm their shared commitment to making high-quality, affordable treatments accessible to patients worldwide TEL AVIV, ISRAEL and MADRID, Oct. 03, 2024 (GLOBE NEWSWIRE) --... Read More

This first-to-market launch showcases Teva’s proven strengths in complex generic formulations and enhances Teva’s strategic goal of sustaining a generic powerhouse. Octreotide acetate for injectable suspension is indicated to treat acromegaly and severe diarrhea for carcinoid syndrome. PARSIPPANY, N.J., Oct. 01, 2024 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and... Read More

TEL AVIV, Israel, Sept. 30, 2024 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it will issue a press release on its financial results for the third quarter of 2024 on Wednesday, November 6, 2024, at 7:00 a.m. ET. Following the release, Teva will conduct a conference call and live webcast on the same day, at 8:00 a.m. ET. In order to participate, please register in advance... Read More

RIM-TD open-label extension (OLE) study showed long-term improvement of Tardive Dyskinesia (TD) symptoms from treatment with deutetrabenazine over three years in European patients 1 TD is an involuntary movement disorder that develops in around 15%-25% of patients taking antipsychotic medications for conditions such as schizophrenia, bipolar disorder, and major depressive disorder 2,3 Data presented at the European College... Read More

As a leader in neuroscience, Teva is committed to researching new treatment innovations that may help address unmet needs in treating schizophrenia , including TEV -‘ 749 Currently, there is no long-acting olanzapine treatment option available for the treatment of schizophrenia that does not contain a boxed warning for Post-Injection Delirium/Sedation Syndrome ( PDSS ) New Phase 3 SOLARIS and Phase 1 safety data show no... Read More

As a leader in neuroscience, Teva remains committed to helping address unmet needs in the treatment of schizophrenia throu gh scientific and clinical advances that support optimal treatment options and decisions for patients and HCPs New data demonstrate s witching to UZEDY at four weeks after the last dose of once-monthly RBP-7000 provided the most comparable pharmacokinetic (PK) profile based on relevant simulations, with... Read More

TEL AVIV, Israel, Sept. 11, 2024 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that Richard Francis, Teva's President and CEO, will present at the Bank of America 2024 Global Healthcare Conference on Thursday, September 19, 2024. The presentation will begin at 8.15 A.M. British summer time (3.15 A.M. Eastern Time). To access a live webcast of the presentation, visit Teva’s... Read More

TEL AVIV, Israel, Aug. 26, 2024 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that Richard Francis, Teva's President and CEO, will present at the Morgan Stanley 22 nd Annual Global Healthcare Conference on Wednesday, September 4, 2024. The presentation will begin at 11:30 A.M. Eastern Time. To access a live webcast of the presentation, visit Teva’s Investor Relations website at... Read More

For an accessible version of this Press Release, please visit www.tevapharm.com Q2 2024 revenues of $4.2 billion reflecting an increase of 7% in U.S. dollars or 11% in local currency terms compared to Q2 2023. Generics business grows across all regions – increased in local currency terms by 16% in the U.S., 8% in Europe and 22% in International Markets, compared to Q2 2023. AUSTEDO – continued growth, U.S. revenue of $407... Read More

Enrollment acceleration drives earlier-than-anticipated data availability for this potentially best-in-class IBD treatment Topline results for both UC and CD now anticipated in Q4 2024 Teva and Sanofi are collaborating to co-develop and co-commercialize duvakitug (anti-TL1A) for moderate-to-severe ulcerative colitis (UC) and Crohn’s disease (CD) patients PARSIPPANY, N.J. & PARIS / Jul 25, 2024 / Business Wire / Teva... Read More

SPACE pediatric Phase 3 study met its primary end point for efficacy with a significantly greater reduction in Monthly Migraine Days compared to placebo Efficacy is consistent with AJOVY (fremanezumab) pivotal Phase 3 and Real-World Evidence studies in adults with no new emergent safety signals observed Full data to be presented at a medical meeting later in 2024 TEL AVIV, Israel / Jul 18, 2024 / Business Wire / Teva... Read More

TEL AVIV, Israel / Jul 02, 2024 / Business Wire / Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it will issue a press release on its second quarter 2024 financial results on Wednesday, July 31, 2024, at 7:00 a.m. ET. Following the release, Teva will conduct a conference call and live webcast on the same day, at 8:00 a.m. ET. In order to participate, please register in advance here to obtain a... Read More

4th interim analysis of PEARL real world migraine prevention study presented at 10th European Association of Neurology (EAN) congress in Helsinki New sub-analysis of PEARL data highlights potential negative impact of treatment pauses on patient outcomes 1 Sub-analysis exploring impact of treatment cessation and reinitiation on migraine prevention suggests potential rise in migraine attacks and diminished treatment... Read More

TEL AVIV, Israel / Jun 25, 2024 / Business Wire / Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it has entered an agreement with the Israel Tax Authority (the "ITA") resolving all pending litigation with respect to taxes payable for the Company's taxable years 2008-2020. Under the terms of the agreement the Company will pay a total of $750 million in installments between 2024 to 2029. This... Read More

Generic Victoza ® is the first-ever generic GLP-1 and supports increased demand for this category of therapies in the U.S. market. This launch adds to Teva’s continued commitment to its complex generic medicine portfolio. Liraglutide injection is indicated to improve glycemic control in adults and pediatric patients aged 10 years and older with type 2 diabetes mellitus and reduce the risk of cardiovascular events in adults... Read More

TEL AVIV, Israel / Jun 04, 2024 / Business Wire / Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that Richard Francis, Teva's President and CEO, will present at the Goldman Sachs 45 th Annual Global Healthcare Conference on Tuesday, June 11, 2024. The presentation will begin at 8:00 A.M. Eastern Time. To access a live webcast of the presentation, visit Teva’s Investor Relations website at... Read More

Switching to UZEDY at four weeks after the last dose of once-monthly paliperidone palmitate provided the most comparable pharmacokinetic (PK) profile based on the relevant PK modeling data Additional data include new Phase 3 RISE and SHINE analyses demonstrating no new or unexpected safety concerns in young adults with schizophrenia treated with UZEDY Global ADVANCE survey findings also reveal real-world experiences and... Read More

Nearly 98% of patients experience quality of life impact as a result of tardive dyskinesia (TD) including social, psychological, physical and recreational aspects of daily living Data highlight for the first time that TD has a multidimensional impact on patients including those with mild TD severity IMPACT-TD Registry is the largest-ever study of its kind evaluating the holistic effects of TD over three years along with... Read More

U.S. FDA approves new one pill, once-daily AUSTEDO XR tablets (30, 36, 42, 48 mg/day) AUSTEDO XR offers more flexibility with the most once-daily doses of any vesicular monoamine transporter 2 (VMAT2) inhibitor for effective and tolerable tardive dyskinesia (TD) and Huntington’s disease (HD) chorea control 1 Patients with TD taking AUSTEDO XR can expect symptom improvement as early as two weeks while patients with HD chorea... Read More

SIMLANDI is the first interchangeable high-concentration, citrate-free biosimilar to Humira ® PARSIPPANY, N.J. & REYKJAVÍK, Iceland / May 20, 2024 / Business Wire / Teva Pharmaceuticals , a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) and Alvotech (NASDAQ: ALVO), today announced the availability of SIMLANDI (adalimumab-ryvk) injection in the U.S., as an interchangeable biosimilar to Humira for... Read More

TEL AVIV, Israel / May 15, 2024 / Business Wire / Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced the appointment of Matthew Shields as Executive Vice President of Teva Global Operations (TGO), the Company’s manufacturing and supply division, effective June 3, 2024. Mr. Shields succeeds Eric Drapé,... Read More

Generics business and AUSTEDO ® growth lead Q1 2024 performance. Q1 2024 revenues of $3.8 billion reflect an increase of 5% in local currency terms, compared to Q1 2023. Generics business growth across all regions – increased by 9% in local currency terms globally, compared to Q1 2023. AUSTEDO – continued growth, up 67% (in the U.S.) from Q1 2023; reaffirming 2024 revenue outlook of ~$1.5 billion. AJOVY ® – revenues of $113... Read More

The study met its primary endpoint achieving clinically meaningful and statistically significant reductions across all TEV-‘749 dose groups versus placebo in the Positive and Negative Syndrome Scale (PANSS) total score, a widely used assessment tool for schizophrenia symptom severity TEV-‘749 was well tolerated, with no incidence of post-injection delirium/sedation syndrome (PDSS) observed to date: additional safety data is... Read More

TEL AVIV, Israel / May 02, 2024 / Business Wire / Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that Richard Francis, Teva's President and CEO, will present at the 2024 Bank of America Healthcare Conference on Tuesday, May 14, 2024. The presentation will begin at 8:40 A.M. Pacific Time (11:40 A.M. Eastern Time). To access a live webcast of the presentation, visit Teva’s Investor Relations website... Read More

Teva’s 2023 Healthy Future Report highlights the Company’s renewed sustainability strategy, which guides Teva in addressing global challenges while also supporting its business, allowing for the continued supply of medicines for patients New ambitious targets are centered on net zero emissions, renewable electricity and a holistic approach to health system strengthening and capacity building to support underserved... Read More

Almost 80% of patients with Huntington's disease (HD) chorea were able to achieve optimal dosing within four weeks with the 4-week Titration Kit in final START study results START study results further support real-world effectiveness, safety, adherence and patient satisfaction with the 4-week Titration Kit for AUSTEDO AUSTEDO remains the only vesicular monoamine transporter 2 (VMAT2) inhibitor available with 3-year data for... Read More

AJOVY confirms efficacy in new Phase 3 data significantly reducing the number of migraine days per month All critical efficacy endpoints met significance as set out apriori through hierarchical testing AJOVY confirmed a favorable safety profile TEL AVIV, Israel & PARSIPPANY, N.J. / Apr 11, 2024 / Business Wire / Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today... Read More

TEL AVIV, Israel / Apr 09, 2024 / Business Wire / Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it will issue a press release on its first quarter 2024 financial results on Wednesday, May 8, 2024, at 7:00 a.m. ET. Following the release, Teva will conduct a conference call and live webcast on the same day, at 8:00 a.m. ET. In order to participate, please register in advance here to obtain a... Read More

PK modeling data provide insights into potential dosing conversions and strategies for switching to UZEDY from a long-acting injectable (LAI) formulation of risperidone microspheres (R064766) Additional UZEDY data include a new analysis from the Phase 3 RISE trial reinforcing its efficacy and safety profile in adults with schizophrenia ADVANCE, a global survey study, will also provide real-world findings on LAI utilization... Read More

Teva and mAbxience enter into a strategic global partnership for in-licensing of an oncology biosimilar candidate Agreement signals a major step in mAbxience's global expansion strategy and advances a key element of Teva’s Pivot to Growth strategy to expand its biosimilar pipeline through business development Teva-mAbxience partnership reflects the companies' shared commitment to expand access to critical healthcare... Read More

Collaboration combines Teva’s expertise in respiratory technology development and Launch Therapeutics’ innovative late-stage drug development model to progress Teva’s Dual-Action Asthma Rescue Inhaler (TEV-‘248) program Development funding agreement to provide up to $150 million to offset program costs and to accelerate clinical research for Teva's TEV-‘248 program in line with Teva's Pivot to Growth strategy to step up... Read More

SHANGHAI & TEL AVIV, Israel / Feb 26, 2024 / Business Wire / Teva Pharmaceutical Investments Singapore Pte Ltd (TPIS), a subsidiary of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) and Jiangsu Nhwa Pharmaceutical Co., Ltd (“Nhwa”) today announced it formed a partnership for the marketing and distribution of Teva’s AUSTEDO (deutetrabenazine) for the treatment of neurodegenerative and movement disorders - chorea... Read More

Results demonstrate rapid and sustained suppression of free TL1A, confirming target engagement of anti-TL1A (TEV-’574) 1 Anti-TL1A (TEV-’574) was shown to be safe and well-tolerated, with a low incidence of antidrug antibodies 2 Data support the ongoing Phase 2b clinical investigation of anti-TL1A (TEV-’574) in inflammatory bowel disease 3 TEL AVIV, Israel & PARSIPPANY, N.J. / Feb 20, 2024 / Business Wire / Teva... Read More

2023 revenues of $15.8 billion reflect an increase of 7% in local currency terms, compared to 2022 AUSTEDO ® - exceeding $1.2 billion in annual revenues, up 28% from 2022; strong growth expected to continue in 2024 with expected revenues of ~$1.5 billion; AJOVY ® - global annual revenues of $435 million, up 16% from 2022; Generics business continues to stabilize, back to revenue growth Q4 2023 and full year 2023 figures... Read More

The intended divestiture is expected to play an important role in Teva's “Pivot to Growth” strategy as it will allow Teva to focus on its core business strengths and on capital allocation towards growth engines and innovation Such intended divestiture of Teva’s API business is expected to enhance TAPI's position as a global leader in the growing API market TEL AVIV, Israel / Jan 31, 2024 / Business Wire / Teva announced... Read More

TEL AVIV, Israel / Jan 02, 2024 / Business Wire / Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it will issue a press release on its fourth quarter and full year 2023 financial results, as well as on its financial guidance for 2024, on Wednesday, January 31, 2024, at 7:00 a.m. ET. Following the release, Teva will conduct a conference call and live webcast on the same day, at 8:00 a.m. ET. In... Read More

TEL AVIV, Israel / Dec 28, 2023 / Business Wire / Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that Richard Francis, Teva's President and CEO, will present at the 42 nd Annual J.P. Morgan Healthcare Conference on Monday, January 8, 2024. The presentation will begin at 8:15 A.M. Pacific Time (11:15 A.M. Eastern Time). To access a live webcast of the presentation, visit Teva’s Investor Relations... Read More

Biolojic’s BD9 is a multibody that was computationally designed as a multi specific antibody targeting IL-13 / TSLP to treat inflammatory diseases. Agreement builds on Teva's Pivot to Growth strategy to step up innovation on Teva's innovative pipeline. Teva to obtain exclusive worldwide rights to develop and commercialize BD9 multibody for potential treatment for Atopic Dermatitis and Asthma TEL AVIV, Israel / Dec 14, 2023 /... Read More

AJOVY ® (fremanezumab) efficacy and safety demonstrated in migraine patients with obesity in post hoc analysis of HALO-LTS 1 and FOCUS 2 phase 3 studies Obesity is a known risk factor for migraine and is frequently associated with an increase in migraine frequency, severity and disability 3 Data revealed at the 17 th European Headache Congress, Barcelona, Spain TEL AVIV, Israel / Dec 06, 2023 / Business Wire / Teva... Read More

PARSIPPANY, N.J. / Nov 30, 2023 / Business Wire / Teva Pharmaceuticals , a U.S. subsidiary of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today closing of its collaboration deal to co-develop and co-commercialize asset TEV ‘574 with Sanofi (EURONEXT: SAN and NASDAQ: SNY). TEV '574 is currently in Phase 2b clinical trials for the treatment of ulcerative colitis and Crohn's disease, two types of... Read More

TEL AVIV, Israel / Nov 20, 2023 / Business Wire / Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that Richard Francis, Teva's President and CEO, will present at the Evercore ISI HealthCONx Conference on Tuesday, November 28, 2023. The presentation will begin at 8:20 A.M. Eastern Time. To access a live webcast of the presentation, visit Teva’s Investor Relations website at... Read More

Forteo® (teriparatide injection) is indicated to treat osteoporosis among certain women and men. This approval showcases Teva’s proven strengths in complex generic formulations development and device engineering. The approval and subsequent launch will enhance access to a critical treatment option for patients while serving to demonstrate Teva’s strategic goal of sustaining a generic powerhouse. PARSIPPANY, N.J. & TEL AVIV,... Read More

Royalty Pharma to provide R&D funding support of up to $125 million for the development of olanzapine LAI (TEV-‘749), a long-acting subcutaneous injectable olanzapine for schizophrenia Phase 3 data expected in the second half of 2024 TEL AVIV, Israel & NEW YORK / Nov 13, 2023 / Business Wire / Teva Pharmaceuticals International GmbH, a subsidiary of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) and Royalty Pharma... Read More

2023 revenues outlook revised to $15.1 - $15.5 billion from $15.0 - $15.4 billion Global revenues of $3.9 billion, reflect an increase of 7% from the third quarter of 2022 Increased revenues reflect sustained growth of AUSTEDO ® , AJOVY ® and global generics business: Growth of AUSTEDO in North America Growth of AJOVY globally Stable and sustainable generics business in the U.S.; continued growth in Europe and International... Read More

TEL AVIV, Israel / Nov 07, 2023 / Business Wire / Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced the appointment of Dr. R. Ananthanarayanan (Ananth) as CEO of its Teva Active Pharmaceutical Ingredients business (Teva api). Dr. Ananth will lead the API business starting November 27, 2023, and will be based out of Teva's U.S. headquarters in Parsippany, NJ. Richard Francis, Teva’s President and CEO... Read More

92% of patients with Huntington's disease (HD) chorea achieved optimal dosing by week 12 with treatment on the AUSTEDO 4-week patient titration kit according to early results from the START study Additional results further reinforce the efficacy and tolerability of AUSTEDO from an analysis of safety and efficacy data across approved vesicular monoamine transporter 2 (VMAT2) inhibitors AUSTEDO remains the only VMAT2 inhibitor... Read More

RISE data show UZEDY to be an effective long-acting injectable (LAI) antipsychotic treatment option for adults with schizophrenia, with a known safety profile consistent with other formulations of risperidone 1 In the RISE study, UZEDY significantly prolonged time to impending relapse by up to 5.0 times (once-monthly dosing) versus placebo in patients with schizophrenia 1 The U.S. Food and Drug Administration (FDA) approved... Read More

Grant funding of $75,000 to each clinic is part of Teva’s $2 million, two-year commitment to support clinics’ innovative mental and behavioral health programs tailored to meet community needs Community Routes is a collaborative effort between Direct Relief, the National Association of Free and Charitable Clinics (NAFC) and Teva Pharmaceuticals to help advance quality mental health care for underserved populations suffering... Read More

Almost half of all migraine patients experience depression and anxiety 1 Migraine patients treated with AJOVY ® (fremanezumab) showed significant reductions in depressive symptoms and clinically meaningful improvements in disability outcomes Data revealed at the World Congress of Neurology, Montreal, Canada TEL AVIV, Israel / Oct 17, 2023 / Business Wire / Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announce... Read More

TEL AVIV, Israel / Oct 06, 2023 / Business Wire / Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it will issue a press release on its third quarter 2023 financial results on Wednesday, November 8, 2023, at 7:00 a.m. ET. Following the release, Teva will conduct a conference call and live webcast, at 8:00 a.m. ET. In order to participate, please register in advance here to obtain a local or... Read More

TEV ‘574, a novel anti-TL1A therapy, is being developed to treat ulcerative colitis and Crohn’s disease Collaboration supports Sanofi’s immunology strategy of exploring novel mechanisms of action for chronic inflammatory diseases Collaboration leverages the innovative R&D and commercial expertise of both companies PARIS & PARSIPPANY, N.J / Oct 04, 2023 / Business Wire / Sanofi (EURONEXT: SAN and NASDAQ: SNY) and Teva... Read More

TEL AVIV, Israel & PARSIPPANY, N.J. / Sep 28, 2023 / Business Wire / Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced changes to its leadership team. Sven Dethlefs, Executive Vice President, North America Commercial, will leave Teva on November 17, 2023, and Christine (Chris) Fox, who most recently served as Global President, Gene Therapies at Novartis will be the new head of Teva’s U.S. Commercial... Read More

TEL AVIV, Israel / Sep 06, 2023 / Business Wire / Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that Richard Francis, Teva's President and CEO, will present at the Morgan Stanley Global Healthcare Conference on Monday, September 11, 2023. The presentation will begin at 8:40 A.M. Eastern Time. To access a live webcast of the presentation, visit Teva’s Investor Relations website at... Read More

Teva will share 16 data presentations across its neuroscience portfolio including AUSTEDO, once-daily AUSTEDO XR, UZEDY, TV-44749 (olanzapine) and AJOVY ® (fremanezumab) injection Presentation highlights include data for AUSTEDO in the tardive dyskinesia (TD) START study on real-world effectiveness and adherence when initiating treatment with a 4-Week Patient Titration Kit and safety data for UZEDY along with results from... Read More

TEL AVIV, Israel & PARSIPPANY, N.J. / Aug 21, 2023 / Business Wire / Teva Pharmaceuticals , a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), has reached a deferred prosecution agreement (DPA) with the U.S. Department of Justice (DOJ) to settle the criminal price-fixing charges brought against Teva in 2020. Under the DPA, which will allow Teva to avoid mandatory exclusion from participation in... Read More

Revenues of $3.9 billion GAAP loss per share of $0.77 Non-GAAP diluted EPS of $0.56 Cash flow generated from operating activities of $324 million Free cash flow of $632 million AUSTEDO ® U.S. revenues of $308 million 2023 revenues outlook revised to $15.0-$15.4 billion from $14.8-$15.4 billion; all other key components reaffirmed: Non-GAAP operating Income of $4.0 – $4.4 billion Adjusted EBITDA of $4.5 - $4.9 billion... Read More

TEL AVIV, Israel / Jul 27, 2023 / Business Wire / Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced the appointment of Dr. Angus Grant, Ph.D., as EVP, Business Development. Dr. Grant will begin his employment on August 1, 2023, and will be based out of Teva's US headquarters in Parsippany, NJ. Dr. Grant joins Teva with over 25 years of experience in the global pharmaceutical and biotech industry, with... Read More

TEL AVIV, Israel & PARSIPPANY, NJ & REYKJAVIK, Iceland / Jul 24, 2023 / Business Wire / Teva Pharmaceuticals, Inc. , a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), a global leader in generic and innovative medicines and Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that they have... Read More

TEL AVIV, Israel / Jul 05, 2023 / Business Wire / Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it will issue a press release on its second quarter 2023 financial results on Wednesday, August 2, 2023 at 7:00 a.m. ET. Following the release, Teva will conduct a conference call and live webcast, at 8:00 a.m. ET. In order to participate, please register in advance here to obtain a local or... Read More

Data presented at the European Academy of Neurology Congress 2023 TEL AVIV, Israel / Jun 30, 2023 / Business Wire / Teva Pharmaceutical Industries Ltd. today announces further positive data from the pan-European PEARL study investigating the impact of AJOVY ® (fremanezumab) on the prevention of migraine in a real-world setting, 1 due to be completed in 2024. The data from the 3 rd interim analysis 2 reveals that almost 60%... Read More

Six abstracts to be presented highlighting results of AJOVY preventive treatment in patients with migraine Oral presentation will feature data from the UNITE study showing that AJOVY significantly reduced migraine days and depression symptoms in patients with migraine and major depressive disorder Findings on AJOVY real-world benefits and potential cost savings will also be presented TEL AVIV, Israel & PARSIPPANY, N.J. / Jun... Read More

TEL AVIV, Israel & PARSIPPANY, N.J. / Jun 12, 2023 / Business Wire / Teva Pharmaceuticals , a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), has reached agreement with the Attorney General of Kentucky to settle the state’s price-fixing claims against Teva. Under the terms of the settlement, Teva will pay the state $1.407 million, and the state will dismiss all of its claims against Teva and its... Read More

Settles with all 50 states and 99 percent of litigating subdivisions Shipments of life-saving generic Narcan ® (naloxone hydrochloride nasal spray) have already begun; payments to states to begin in the second half of 2023 Separate settlement reached with the final state of Nevada TEL AVIV, Israel & PARSIPPANY, N.J. / Jun 08, 2023 / Business Wire / Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd.... Read More

Via the PhilRx Patient Access Platform, patients can now access Teva Pharmaceuticals’ Digihaler® family of inhalers SAN FRANCISCO / Jun 06, 2023 / Business Wire / Phil Inc ., a patient access platform company that revolutionizes life science product commercialization, today announced an agreement with Teva Pharmaceuticals that will make Digihaler® products available for prescription using the PhilRx Patient Access Platform.... Read More

START study provides real-world data for AUSTEDO with the use of a 4-week patient titration kit for adults with tardive dyskinesia (TD), including utilization and patient satisfaction AUSTEDO is the only vesicular monoamine transporter 2 (VMAT2) inhibitor with 3-year long-term data 1,2 approved for adults with TD and chorea associated with Huntington’s disease (HD) Additional presentations include long-term safety, and... Read More

UZEDY significantly reduced the risk of relapse by up to 80% and prolonged the time to impending relapse by up to 5.0 times while having a similar safety profile to other formulations of risperidone 1,2 The U.S. Food and Drug Administration (FDA) approved UZEDY on April 28, 2023 for the treatment of schizophrenia in adults as a subcutaneous injection every one or two months using a pre-filled syringe Symposia on IMPACT-TD... Read More

Return to growth by accelerating a strong innovative medicines portfolio Expand innovative pipeline and focus on core therapeutic areas with first-in-class and best-in-class opportunities Sustain generics powerhouse based on high-value and complex products Focus the business on areas with the greatest potential for growth and patient impact TEL AVIV, Israel / May 18, 2023 / Business Wire / Teva Pharmaceutical Industries Ltd.... Read More

New once-daily option for the treatment of adults with tardive dyskinesia (TD) and chorea associated with Huntington’s disease (HD) is available in 6 mg, 12 mg, and 24 mg tablet strengths and can be taken with or without food Once-daily AUSTEDO XR has been shown to be therapeutically equivalent to twice-daily AUSTEDO, providing another effective treatment choice for TD and HD chorea patients 1 In the longest TD clinical... Read More

TEL AVIV, Israel / May 10, 2023 / Business Wire / Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today reported results for the quarter ended March 31, 2023. Revenues of $3.7 billion GAAP loss per share of $0.18 Non-GAAP diluted EPS of $0.40 Cash flow used in operating activities of $145 million Free cash flow of $41 million Non-GAAP gross profit margin of 49.1% was mainly impacted by an unfavorable portfolio mix... Read More

Launched five access to medicines programs as of 2022 (63% of 2025 target); donated $699.6 million worth of medicines to patients in need Reduced absolute scope 1 and 2 greenhouse gas (GHG) emissions by 24% (vs. 2019) and absolute scope 3 GHG emissions by 12% (vs. 2020); met or exceeded 2030 targets to increase energy efficiency and reduce total water withdrawal in areas projected to be in water stress Ranked in the top 10%... Read More

“Community Routes: Access to Mental Health Care” helps uninsured patients access healthcare for anxiety and depression, and is a partnership between Direct Relief, the National Association of Free and Charitable Clinics (NAFC) and Teva Pharmaceuticals The expansion of medicine donations for anxiety and depression into​ seven new states across the United States has the potential to extend the program’s reach to more than... Read More

This new treatment provides adults living with schizophrenia a long-acting formulation that offers flexible 1- and 2-month dosing intervals 1 In a Phase 3 clinical trial, UZEDY demonstrated up to 80% reduction in risk of schizophrenia relapse versus placebo 1 UZEDY is a subcutaneous injection from a pre-filled syringe with a 21-gauge needle PARSIPPANY, N.J., TEL AVIV & PARIS / Apr 28, 2023 / Business Wire / Teva... Read More

TEL AVIV, Israel / Apr 27, 2023 / Business Wire / Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it will host an Investor Day on Thursday, May 18, 2023 to launch its new growth strategy and portfolio priorities. The event will take place at the New York Stock Exchange in New York City. Presentations will begin at 12:00 p.m. Eastern Time and are expected to conclude at 2:00 p.m. Eastern Time.... Read More

TEL AVIV, Israel / Apr 14, 2023 / Business Wire / Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it will issue a press release on its first quarter 2023 financial results on Wednesday, May 10, 2023 at 7:00 a.m. ET. Following the release, Teva will conduct a conference call and live webcast on the same day, at 8:00 a.m. ET. In order to participate, please register in advance here to obtain a... Read More

TEL AVIV, Israel & PARSIPPANY, N.J. / Apr 13, 2023 / Business Wire / Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced that the U.S. Food and Drug Administration (FDA) has issued a complete response letter (CRL) to its partner Alvotech (NASDAQ: ALVO) for the Biologics License Application (BLA) for AVT02, a high-concentration biosimilar candidate for Humira ® (adalimumab). The CRL stated that the application... Read More

Dose proportionality and bioequivalence studies demonstrate once-daily AUSTEDO XR is therapeutically equivalent to twice-daily AUSTEDO ® (deutetrabenazine) tablets The U.S. Food and Drug Administration (FDA) approved once-daily AUSTEDO XR extended-release tablets on February 17, 2023 AUSTEDO is the only vesicular monoamine transporter 2 (VMAT2) inhibitor approved for both tardive dyskinesia and chorea associated with... Read More

California’s Desert Oasis Healthcare (DOHC) implements Rimidi’s Respiratory Module for respiratory patient monitoring, based on data collected by Teva’s Digihaler® System Digihaler is the first and only smart inhaler system that can provide objective data to help patients and their doctors better support asthma management Teva and Rimidi look to expand respiratory monitoring program to additional health systems with the aim... Read More

TEL AVIV, Israel / Mar 13, 2023 / Business Wire / Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) (“ Teva ”) announced today the early tender results in connection with its previously announced tender offers (the “ Offers ”) and that it is increasing the tender caps as specified below for the following series of notes issued by finance subsidiaries of Teva and guaranteed by Teva: 7.125% Senior Notes due 2025, CUSIP... Read More

PARSIPPANY, N.J. & TEL AVIV, Israel & HYDERABAD, India / Mar 09, 2023 / Business Wire / Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), and NATCO Pharma Limited (NSE: NATCOPHARM; BSE: 524816), announced today the launch of additional strengths for the generic version of Revlimid® 1 (lenalidomide capsules), in 2.5 mg, and 20 mg strengths, in the United States. The companies... Read More

TEL AVIV, Israel & PARSIPPANY, N.J. / Mar 07, 2023 / Business Wire / Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that Eli Kalif, EVP and Chief Financial Officer will present at the Barclays Global Healthcare Conference on Tuesday, March 14, 2023. The presentation will begin at 10:15 A.M. Eastern Time. To access a live webcast of the presentation, visit Teva’s Investor Relations website at... Read More

TEL AVIV, Israel / Mar 01, 2023 / Business Wire / Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) (“ Teva ”) announced today that it successfully upsized its offering and priced approximately $2,490,000,000 (equivalent) of its sustainability-linked senior notes (the “ Notes ”). The principal amount of the offering was increased from the previously announced offering size of $2,060,000,000 (equivalent) and the... Read More

TEL AVIV, Israel / Feb 27, 2023 / Business Wire / Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) (“ Teva ”) announced today that it has commenced tender offers (the “ Offers ”) to purchase for cash for a combined aggregate purchase price (exclusive of accrued and unpaid interest) of up to $2,250,000,000 (the “ Total Maximum Amount ”) of the following series of notes issued by finance subsidiaries of Teva and... Read More

TEL AVIV / Feb 27, 2023 / Business Wire / Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) (“ Teva ”) announced today its intention to issue $2,060,000,000 (equivalent) of sustainability-linked senior notes. The notes offering reflects Teva’s continued strong commitment to sustainable finance to help address some of the greatest challenges of our time. The sustainability-linked senior notes are to be issued under... Read More

TEL AVIV, Israel & PARSIPPANY, N.J. / Feb 24, 2023 / Business Wire / Teva Pharmaceuticals USA, Inc., a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced that new data on its Digihaler System will be presented at the American Academy of Allergy, Asthma and Immunology (AAAAI) 2023 Annual Meeting, being held February 24-27 in San Antonio, Texas. The data includes findings from the... Read More

TEL AVIV, Israel & PARSIPPANY, N.J. / Feb 23, 2023 / Business Wire / Teva Pharmaceuticals , a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced the print publication of the IMPACT-TD Scale, an easy-to-use, standardized and clinician-rated assessment. The scale, developed by a consensus panel, will assist healthcare providers in determining the impact of tardive dyskinesia (TD) on... Read More

TEL AVIV, Israel & PARSIPPANY, N.J. / Feb 17, 2023 / Business Wire / Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced that the U.S. Food and Drug Administration (FDA) has approved AUSTEDO XR (deutetrabenazine) extended-release tablets, a new once-daily formulation indicated in adults for tardive dyskinesia (TD) and chorea associated with Huntington’s disease... Read More

TEL AVIV, Israel & PARSIPPANY, N.J. / Feb 09, 2023 / Business Wire / Teva Pharmaceuticals , a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), has reached agreement with the Attorney General of Florida to settle the state’s price-fixing claims against Teva. Under the terms of the settlement, Teva will pay the state $6.73 million, and the state will dismiss all of its claims against Teva and its... Read More

TEL AVIV, Israel / Feb 08, 2023 / Business Wire / Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today reported results for the year and the quarter ended December 31, 2022. Q4 and FY 2022 highlights: Q4 2022 FY 2022 Revenues $3.9 billion $14.9 billion GAAP diluted loss per share $(1.10) $(2.12) Non-GAAP diluted EPS $0.71 $2.52 Cash flow generated from operating activities $973 million $1,590 million Free cash... Read More

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that its targets to reduce greenhouse gas (GHG) emissions have been approved by the Science Based Targets initiative (SBTi), providing external validation of the Company’s ambitious commitments to minimize its environmental footprint. As one of the world's largest manufacturers of generic medicines, Teva makes treatments more affordable and accessible... Read More

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it will issue a press release on its fourth quarter and full year 2022 financial results, as well as on its financial guidance for 2023, on Wednesday, February 8, 2023 at 7:00 a.m. ET. Following the release, Teva will conduct a conference call and live webcast on the same day, at 8:00 a.m. ET. In order to participate, please register in advance... Read More

Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today confirmed a sufficient level of participation to move forward with its nationwide settlement agreement to resolve opioid-related claims and litigation by states, cities, counties, and other subdivisions in the United States. Teva has either already settled with or confirmed participation from 48 of the 50 states and will... Read More

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that members of management will present at the 41 st Annual J.P. Morgan Healthcare Conference on Wednesday, January 11, 2023. The presentation will begin at 10:30 A.M. Pacific Time (1:30 P.M. Eastern Time). To access a live webcast of the presentation, visit Teva’s Investor Relations website at http://ir.tevapharm.com/ . An archived version of the... Read More